EP2358745B1 - Leukolectins and uses thereof - Google Patents

Leukolectins and uses thereof Download PDF

Info

Publication number
EP2358745B1
EP2358745B1 EP09745090.2A EP09745090A EP2358745B1 EP 2358745 B1 EP2358745 B1 EP 2358745B1 EP 09745090 A EP09745090 A EP 09745090A EP 2358745 B1 EP2358745 B1 EP 2358745B1
Authority
EP
European Patent Office
Prior art keywords
sequence
set forth
nos
amino acid
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP09745090.2A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2358745A1 (en
Inventor
Bernt Th Walther
Mirushe Miftari
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LEUKOLECT AS
Original Assignee
LEUKOLECT AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LEUKOLECT AS filed Critical LEUKOLECT AS
Publication of EP2358745A1 publication Critical patent/EP2358745A1/en
Application granted granted Critical
Publication of EP2358745B1 publication Critical patent/EP2358745B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1706—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4726—Lectins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity

Definitions

  • the present invention relates to a polypeptide, namely a lectin, its encoding nucleic acid sequence and antibodies to the polypeptide and their use in various medical applications.
  • the cellular immune defence system is central to surviving microbial and parasitic challenges. This system is also most relevant for managing deviant cells in carcinogenesis, after viral infections and in autoimmune diseases.
  • autoimmunity can be demonstrated by the presence of autoantibodies or T lymphocytes reactive with host antigens. Whilst it is usually harmless and probably a universal phenomenon of vertebrate life, autoimmunity can be the cause of a broad spectrum of human illnesses, known as autoimmune diseases. This concept of autoimmunity as the cause of human illness is relatively new, and it was not accepted into the mainstream of medical thinking until the 1950s and 1960s. Autoimmune diseases are defined as diseases in which the progression from benign autoimmunity to pathogenic autoimmunity occurs. This progression is determined by both genetic influences and environmental triggers.
  • Autoimmune diseases are a major threat to health. There are more than eighty illnesses caused by autoimmunity. They are a special threat to women; about 75% of the patients are women. Autoimmune diseases are among the ten leading causes of death among women in all age groups up to 65.
  • Autoimmune diseases affect many different parts of the body including the skin (e.g. alopecia areata, bullous pemphigoid, epidermolysis bullosa acquisita, pemphigus foliaceous, pemphigus vulgaris, vitiligo, psoriasis and acne), kidney (e.g. IgA nephropathy), blood (e.g. aplastic anemia, autoimmune hemolytic anemias, idiopathic thrombocytopenic purpura and, pernicious anemia), joints (e.g. ankylosing spondilitis), muscles (e.g. polymyositis/dermatomyositis), ear (e.g.
  • autoimmune hearing loss and Meniere's syndrome e.g. Mooren's ulcer, Reiter's syndrome and Vogt-Koyanagi-Harada disease
  • eye e.g. Mooren's ulcer, Reiter's syndrome and Vogt-Koyanagi-Harada disease
  • heart e.g. autoimmune myocarditis, Churg-Strauss syndrome, giant cells arteritis, Kawasaki's disease, polyarteritis nodosa, Takayasu's arteritis and Wegener's granulomatosis
  • endocrine system e.g.
  • Addison's disease autoimmune hypoparathyroidism, autoimmune hypophysitis, autoimmune oophoritis, autoimmune orchitis, Graves' disease, Hashimoto's thyroiditis, polyglandular autoimmune syndrome type 1 (PAS-1), polyglandular autoimmune syndrome type 2 (PAS-2), polyglandular autoimmune syndrome type 3 (PAS 3) and type 1 diabetes mellitus), gasteroenteric system (e.g. autoimmune hepatitis, celiac disease, inflammatory bowel disease and primary biliary cirrhosis), nervous system (e.g.
  • chronic inflammatory demyelinating polyneuropathy Guillan-Barre syndrome, multiple sclerosis and myasthenia gravis
  • may affect the body systemically e.g. antiphospholipid syndrome, autoimmune lymphoproliferative, autoimmune polyendocrinopathy, Bechet's disease, Goodpasture's syndrome, rheumatoid arthritis, sarcoidosis, scleroderma, Sjogren's syndrome and systemic lupus erythematosus).
  • autoimmune diseases can strike any part of the body, and thus symptoms vary widely and diagnosis and treatment are often difficult. Some autoimmune diseases can be life threatening unless properly diagnosed and treated. Chronic autoimmune disorders like rheumatoid arthritis cripple the patient and also create heavy burdens on patients' families. Some types of uveitis may cause blindness. Diseases such as scleroderma require skillful, lifelong treatment. Still other autoimmune diseases, including Graves' disease and chronic thyroiditis, can be successfully treated if correctly diagnosed, but they are frequently missed because of their subtle onset.
  • Inflammation is a normal process in which the body's white blood cells and chemicals protect the body from infection and foreign substances such as bacteria and viruses. In some diseases, however, the body's immune system inappropriately triggers an inflammatory response when there are no foreign substances to fight off. Inflammation is thus common in autoimmune diseases, but not all inflammatory disorders are autoimmune responses. Inflammatory diseases may also be caused by a wide variety of agents which directly attack the body such as microorganisms (viruses and fungii), bacterial toxins, certain pharmaceutical agents (antibiotics and anti-inflammatory steroids), and chemical agents (bile salts, toxic household chemicals).
  • arthritis which is a general term that describes inflammation in joints
  • inflammation of the heart myocarditis
  • inflammation of the small tubes that transport air to the lungs which may cause an asthma attack
  • inflammation of the kidneys nephritis
  • inflammation of the large intestine colitis
  • Gastrointestinal inflammatory disorders are of particular interest e.g. gastric inflammatory diseases (such as gastric ulcer, duodenal ulcer and gastritis), and intestinal inflammatory diseases (including Crohn's disease, inflammatory bowel disease, tropical and non-tropical sprue, infectious enteritis, colitis, ulcerative colitis, pseudomembranous colitis, diverticulitis, and allergenic and radiological inflammatory diseases).
  • gastric inflammatory diseases such as gastric ulcer, duodenal ulcer and gastritis
  • intestinal inflammatory diseases including Crohn's disease, inflammatory bowel disease, tropical and non-tropical sprue, infectious enteritis, colitis, ulcerative colitis, pseudomembranous colitis, diverticulitis, and allergenic and radiological inflammatory diseases.
  • Gastrointestinal inflammatory diseases are characterized by inflammation, specifically by the presence of edema, characteristic inflammatory cells (i.e., leucocytes, histiocytes, and macrophages), and, in some cases, necrosis and ulceration of the surface epithelium.
  • These inflammatory diseases are known to be caused by a wide variety of agents present in the gastrointestinal tract which are known to attack the surfaces thereof, producing the inflammatory disease response.
  • agents include microorganisms (viruses and fungii), bacterial toxins, certain pharmaceutical agents (antibiotics and anti-inflammatory steroids), and chemical agents (bile salts, toxic household chemicals). Indeed, gastric acid itself is capable of attacking the stomach lining and producing the inflammatory state.
  • Non-steroidal anti-inflammatory drugs such as aspirin, ibuprofen or naproxen
  • corticosteroids such as prednisone
  • anti-malarial medications such as hydroxychloroquine
  • other medications such as methotrexate, sulfasalazine, leflunomide, anti-TNF medications, cyclophosphamide and mycophenolate.
  • Some gastrointestinal diseases, specifically gastric diseases may be treated by inhibition of gastric acid secretion which causes the inflammation, such as by neutralizing the effects of the acid (e.g., antacid administration), or by administration of a pharmacological agent effective to inhibit gastric acid secretion.
  • Damaged skin is vulnerable to infection and may be unsightly and/or cause pain or discomfort. Some types of wounds are resistant to healing under normal physiological conditions, e.g. chronic ulcers. Any pharmaceutical solutions to repair damaged skin, particularly to repair wounds are very desirable.
  • leukolectin a new protein (herein referred to as leukolectin), - not only in gametes and in the zygote, but also in the early embryo (in specialised cells denoted lectocytes), and during ontogeny of blood cells, and finally, in leukocytes.
  • the protein was identified in and purified from fish (see the Examples).
  • the protein has 255 amino acids. This is the propeptide form of the lectin, which contains a 19 amino acid N-terminal peptide which suggests that it is targeted to the lysosome for later secretion (i.e. into the perivitelline space).
  • the amino acid sequence of the lectin allowed the development of epitope-specific antibodies, which in turn enabled the identification of many (2-8) seeming isoforms of the protein ( Figure 5 ), depending on the tissue analyzed. At least two mRNAs have been isolated from salmon (see Example 11), which contain minor sequence differences that result in only 7 changes at the polypeptide level ( Figure 17 ). Truncated forms of the protein have also been identified from salmon leukocytes (see SEQ ID NO: 2) and zebrafish, in which a secreted form (as described above, denoted sLL) and a truncated form which is missing the first 32 amino acids from the N-terminus, denoted tLL (see Example 9) have been identified.
  • the protein bears little resemblance to any known proteins, showing overall similarity of less than 50% to any known protein. Some similarity was observed in small domains to tachylolectins.
  • this novel gene is specifically expressed in human leukocytes, despite the fact that this gene cannot be found in published sequences of the human genome. Only very short segments of this gene may be detected but spread over multiple human chromosomes (see the Examples). The resolution of this conundrum is as yet not at hand.
  • leukolectin binds to specific receptors which set in motion the normal and inherent healing processes of the human body. From the observed effects we propose that leukolectin participates in the normal process of cellular immunity.
  • Leukolectin seem to be missing in many disease states, so that its pharmaceutical introduction triggers other defensive responses of the immune system to perform normally in the face of various challenges: the presence of foreign cells (microbes, parasites) and of altered cells of the "self” which may tie leukolectin to the etiology of auto-immune diseases, i.e., such conditions may be caused by the absence of sufficient leukolectin.
  • Leukolectin proteins Human leukocytes contain and express extremely conserved leukolectin proteins. Until now, these proteins were unknown proteins in blood cells. Leukolectin appear to be a new member of the tachylolectin family of proteins.
  • polypeptide comprising:
  • Polypeptides as referred to herein are molecules with preferably more than 200 or 250 residues and/or less than 500, 400 or 300 residues or a range selected therefrom.
  • a "portion" preferably comprises at least 200 or more amino acids of the sequence from which it is derived. Said portion may be obtained from a central or N-terminal or C-terminal portions of the sequence. Preferably said portion is obtained from the N-terminal end, e.g. from the first 50, 100 or 150 residues of the polypeptide.
  • Preferred aspects include truncations of said polypeptides, e.g. to remove a signal peptide or portion absent in naturally occurring variants. Preferred truncations occur at the N-terminal end and are from 1 to 50, e.g. 1 to 10, 20, 30 or 40, or 5 to 40, e.g. 10 to 35 residues in length.
  • said sequence is at least 95, 96, 97, 98 or 99% identical to the sequence to which it is compared.
  • Sequence identity may be determined by, e.g. using the SWISS-PROT protein sequence databank using FASTA pep-cmp with a variable pamfactor, and gap creation penalty set at 12.0 and gap extension penalty set at 4.0, and a window of 2 amino acids. Preferably said comparison is made over the full length of the sequence, but may be made over a smaller window of comparison, e.g. less than 200, 100 or 50 contiguous amino acids.
  • sequence identity related polypeptides are functionally equivalent to the polypeptides which are set forth in the recited Sequence Nos.
  • Such functionally equivalent polypeptides may take the form of derivatives as set forth below.
  • the polypeptides with sequences as set forth in the Sequence Nos. may be modified without affecting the sequence of the polypeptide as described below.
  • portions as described herein may be functional equivalents. Preferably these portions satisfy the identity (relative to a comparable region) conditions mentioned herein.
  • the polypeptide may show some reduced efficacy in performing the medical function relative to the parent molecule (i.e. the molecule from which it was derived, e.g. by amino acid substitution), but preferably is as efficient or is more efficient.
  • functional equivalence relates to a polypeptide which is effective to treat a disease as referred to herein, i.e. to reduce one or more symptoms of the patient, e.g. inflammation or the appearance of the skin as described hereinafter. This may be tested by comparison of the effects of the derivative polypeptide relative to the polypeptide from which it is derived in a qualitative or quantitative manner, e.g.
  • the derivative is at least 30, 50, 70 or 90% as effective as the parent polypeptide.
  • in vitro testing may be performed, e.g. by analysis of binding to dendritic cells or effects on in vitro cell cultures.
  • Functionally-equivalent proteins which are related to or derived from the naturally-occurring protein, may be obtained by modifying the native amino acid sequence by single or multiple amino acid substitution, addition and/or deletion (providing they satisfy the above-mentioned sequence identity requirements), but without destroying the molecule's function.
  • the native sequence has less than 20 substitutions, additions or deletions, e.g. less than 10, 5, 4, 3, 2, or 1 such modifications.
  • Such proteins are encoded by "functionally-equivalent nucleic acid molecules" which are generated by appropriate substitution, addition and/or deletion of one or more bases.
  • Preferred functional equivalents are "addition" variants in which amino and/or carboxy terminal fusion proteins or polypeptides are generated, comprising an additional protein or polypeptide fused to the parent polypeptide.
  • Particularly preferred functionally-equivalent variants are natural biological variations (e.g. allelic variants or geographical variations within a species or alternatively in different genera, e.g. plants, animals or bacteria) and derivatives prepared using known techniques.
  • nucleic acid molecules encoding functionally-equivalent proteins may be produced by chemical synthesis or in recombinant form using the known techniques of site-directed mutagenesis including deletion, random mutagenesis, or enzymatic cleavage and/or ligation of nucleic acids.
  • the present invention also provides nucleotide sequences encoding said polypeptides, said nucleic acid molecule comprising:
  • Nucleic acid molecules as referred to herein are molecules with preferably more than 600 or 750 bases and/or less than 1500, 1200 or 900 bases or a range selected therefrom.
  • Portions as referred to above, preferably comprise at least 600 nucleotide bases of the sequence from which it is derived. Preferably said portions encode N-terminal, central or C-terminal peptides as described hereinbefore. As discussed above in relation to polypeptides, in a preferred aspect truncations resulting in removal of residues from the N-terminal end of the recited polypeptides is contemplated.
  • said truncation is preferably from 1 to 150, e.g. 1 to 30, 60, 90 or 120, or 13 to 120, e.g. 28 to 105 bases in length.
  • said sequence is at least 98 or 99% identical to the sequence to which it is compared.
  • Sequence identity may be determined by, e.g. FASTA Search using GCG packages, with default values and a variable pamfactor, and gap creation penalty set at 12.0 and gap extension penalty set at 4.0 with a window of 6 nucleotides.
  • sequence identity related or hybridizing nucleic acid molecules are functionally equivalent to the nucleic acid molecules which are set forth in the recited Sequence Nos.
  • Such functionally equivalent nucleic acid molecules may take the form of derivatives as set forth below and are considered functionally equivalent if they encode polypeptides which would be considered functional equivalents according to the tests described hereinbefore.
  • Preferred functional equivalents are those which encode the preferred polypeptides as set out above, e.g. nucleic acid molecules which encode polypeptides found in different genera or species than the specific molecules mentioned herein.
  • portions as described herein may be functional equivalents. Preferably these portions satisfy the identity (relative to a comparable region) or hybridizing conditions mentioned herein.
  • Nucleic acid molecules according to the invention may be single or double stranded DNA, cDNA or RNA, preferably DNA and include degenerate, substantially identical and hybridizing sequences as described above. Ideally however the molecules are DNA or cDNA.
  • polypeptides as described above include those which are modified without affecting the sequence of the polypeptide, e.g. by chemical modification, including by deglycosylation or glycosylation.
  • Such polypeptides may be prepared by post-synthesis/isolation modification of the polypeptide without affecting functionality, e.g. certain glycosylation, methylation etc. of particular residues.
  • polypeptides of the invention may also take the form of peptidomimetics which may be considered derivatives in which the functional features of the polypeptide are retained but are presented in the context of a different, e.g. non-peptide structure.
  • peptidomimetics have successfully been developed and used for other particularly medical applications.
  • Peptidomimetics particularly non-peptidic molecules may be generated through various processes, including conformational-based drug design, screening, focused library design and classical medicinal chemistry. Not only may oligomers of unnatural amino acids or other organic building blocks be used, but also carbohydrates, heterocyclic or macrocyclic compounds or any organic molecule that comprises structural elements and conformation that provides a molecular electrostatic surface that mimics the same properties of the 3-dimensional conformation of the peptide may be used by methods known in the art.
  • peptidomimetics may bear little or no resemblance to a peptide backbone.
  • Peptidomimetics may comprise an entirely synthetic non-peptide form (e.g. based on a carbohydrate backbone with appropriate substituents) or may retain one or more elements of the peptide on which it is based, e.g. by derivatizing one or more amino acids or replacing one or more amino acids with alternative non-peptide components.
  • Peptide-like templates include pseudopeptides and cyclic peptides. Structural elements considered redundant for the function of the peptide may be minimized to retain a scaffold function only or removed where appropriate.
  • peptidomimetics retain one or more peptide elements, i.e. more than one amino acid, such amino acids may be replaced with a non-standard or structural analogue thereof.
  • Amino acids retained in the sequences may also be derivatised or modified (e.g. labelled, glycosylated or methylated) as long as the functional properties of the polypeptides of the invention are retained.
  • the peptidomimetics are referred to as being "derivable from" a certain polypeptide sequence. By this it is meant that the peptidomimetic is designed with reference to a defined polypeptide sequence, such that it retains the structural features of the peptide which are essential for its function.
  • This may be the particular side chains of the polypeptide, or hydrogen bonding potential of the structure.
  • Such features may be provided by non-peptide components or one or more of the amino acid residues or the bonds linking said amino acid residues of the polypeptide may be modified so as to improve certain functions of the polypeptide such as stability or protease resistance, while retaining the structural features of the polypeptide which are essential for its function.
  • non-standard or structural analogue amino acids which may be used are D amino acids, amide isosteres (such as N-methyl amide, retro-inverse amide, thioamide, thioester, phosphonate, ketomethylene, hydroxymethylene, fluorovinyl, (E)-vinyl, methyleneamino, methylenethio or alkane), L-N methylamino acids, D- ⁇ methylamino acids, D-N-methylamino acids. Examples of non-conventional amino acids are listed in Table 1.
  • Non-conventional amino acid Code Non-conventional amino acid Code ⁇ -aminobutyric acid Abu L-N-methylalanine Nmala ⁇ -amino- ⁇ -methylbutyrate Mgabu L-N-methylarginine Nmarg aminocyclopropane- Cpro L-N-methylasparagine Nmasn carboxylate L-N-methylaspartic acid Nmasp aminoisobutyric acid Aib L-N-methylcysteine Nmcys aminonorbornyl- Norb L-N-methylglutamine Nmgln carboxylate L-N-methylglutamic acid Nmglu cyclohexylalanine Chexa L-N-methylhistidine Nmhis cyclopentylalanine Cpen L-N-methylisolleucine Nmile D-alanine Dal L-N-methylleucine Nmleu D-arginine Darg L-N-methyllysine Nmlys D-aspartic
  • Non-standard amino acids which may be used include conformationally restricted analogs, e.g. such as Tic (to replace F), Aib (to replace A) or pipecolic acid (to replace Pro).
  • conformationally restricted analogs e.g. such as Tic (to replace F), Aib (to replace A) or pipecolic acid (to replace Pro).
  • polypeptides and nucleic acid molecules discussed above also include derivatives which have been modified, e.g. to facilitate their use in pharmaceutical applications (discussed below), e.g. by the addition of targeting or functional groups, e.g. to improve lipophilicity, aid cellular transport, solubility and/or stability.
  • oligosaccharides, fatty acids, fatty alcohols, amino acids, peptides or polypeptides may be conjugated to the aforementioned polypeptides or nucleic acid molecules.
  • Nucleic acid molecules may be present in a viral carrier as described hereinafter.
  • polypeptides also encompass derivatives in the form of "pro-drugs" or "pro-peptides” such that the added component may be removed by cleavage once administered, e.g. by cleavage of a substituent added through esterification which may be removed by the action of esterases.
  • pro-drugs include native precursors of the naturally occurring proteins which are cleaved e.g. by proteolysis to yield the polypeptide of interest. Such precursors may be inactive in the precursor form but may be activated by proteolytic cleavage.
  • the nucleic acid molecules of the invention thus similarly encompass molecules which encode such pro-drugs or precursors. Modified polypeptides or nucleic acid molecules as described above may be tested to ensure that they retain functional activity relative to the unmodified molecule by determining if they have the same or similar medical effects.
  • the nucleic acid molecules described above may be operatively linked to an expression control sequence, or a recombinant DNA cloning vehicle or vector containing such a recombinant DNA molecule.
  • This allows intracellular expression of the polypeptide of the invention as a gene product, the expression of which is directed by the gene(s) introduced into cells of interest.
  • Gene expression is directed from a promoter active in the cells of interest and may be inserted in any form of linear or circular DNA vector for incorporation in the genome or for independent replication or transient transfection/expression. Suitable transformation or transfection techniques are well described in the literature.
  • the naked DNA molecule may be introduced directly into the cell for the uses described herein.
  • Appropriate expression vectors include appropriate control sequences such as for example translational (e.g. start and stop codons, ribosomal binding sites) and transcriptional control elements (e.g. promoter-operator regions, termination stop sequences) linked in matching reading frame with the nucleic acid molecules required for performance of the method of the invention as described hereinafter.
  • Appropriate vectors may include plasmids and viruses (including both bacteriophage and eukaryotic viruses). Suitable viral vectors include baculovirus and also adenovirus, adeno-associated virus, herpes and vaccinia/pox viruses. Many other viral vectors are described in the art.
  • Preferred vectors include bacterial and mammalian expression vectors pGEX-KG, pEF-neo and pEF-HA.
  • the nucleic acid molecule may conveniently be fused with DNA encoding an additional polypeptide, e.g. glutathione-S-transferase, to produce a fusion protein on expression.
  • the present invention provides a vector, preferably an expression vector, comprising a nucleic acid molecule as defined above.
  • aspects of the invention include methods for preparing recombinant nucleic acid molecules according to the invention, comprising inserting nucleotide sequences encoding the polypeptides of the invention into vector nucleic acid.
  • the polypeptides may be administered to a cell by transfection of a cell with a nucleic acid molecule of the invention.
  • the present invention thus extends to nucleic acid molecules comprising a sequence which encodes the polypeptides of the invention as described herein and their use in methods described herein.
  • said nucleic acid molecules are contained in a vector, e.g. an expression vector.
  • Nucleic acid molecules of the invention may be introduced into a cell by any appropriate means. Suitable transformation or transfection techniques are well described in the literature. A variety of techniques are known and may be used to introduce such vectors into prokaryotic or eukaryotic cells for expression. Preferred host cells for this purpose include insect cell lines, eukaryotic cell lines or E. coli, such as strain BL21/DE3. The invention also extends to transformed or transfected prokaryotic or eukaryotic host cells containing a nucleic acid molecule, particularly a vector as defined above.
  • a further aspect of the invention provides a method of preparing a polypeptide of the invention as hereinbefore defined, which comprises culturing a host cell containing a nucleic acid molecule as defined above, under conditions whereby said polypeptide is expressed and recovering said molecule thus produced.
  • the expressed polypeptide forms a further aspect of the invention.
  • the invention also extends to a polypeptide encoded by a nucleic acid molecule as hereinbefore described. This may be produced by expression in a host cell as described above.
  • Cells containing polypeptides of the invention, but which have been modified relative to native cells by direct introduction of said polypeptides or by expression of encoding nucleic acid material form further aspects of the invention.
  • said polypeptides or nucleic acids molecules do not appear in said cells endogenously, i.e. said cell is modified to contain exogenous polypeptides or nucleic acid material.
  • the present invention also extends to antibodies (monoclonal or polyclonal) and their antigen-binding fragments (e.g. F(ab) 2 , Fab and Fv fragments, i.e. fragments of the "variable" region of the antibody, which comprises the antigen binding site) directed specifically to the polypeptides as defined hereinbefore.
  • antigen-binding fragments e.g. F(ab) 2 , Fab and Fv fragments, i.e. fragments of the "variable" region of the antibody, which comprises the antigen binding site
  • the antibodies described herein may be used in vitro to identify the presence or amount of the polypeptide of the invention and may be used diagnostically to identify disorders or skin damage as described herein associated with aberrant levels of said polypeptide, i.e. variation relative to normal levels, e.g. elevated or reduced levels of said polypeptide.
  • a method is disclosed herein of determining the presence or amount of a polypeptide of the invention or a portion thereof in a sample, wherein an antibody as herein described is brought into contact with said sample and the extent of antibody binding is indicative of the present or amount of said polypeptide or portion thereof.
  • the sample which is assessed may be any convenient sample, e.g. blood or a tissue sample or non-biological sample.
  • the sample is derived from an animal as described herein, preferably a human.
  • a method is disclosed herein of diagnosing a disorder or skin damage as described herein in an animal, comprising at least the steps of determining the presence or amount of a polypeptide as described herein in a sample from said animal, wherein said presence or amount is diagnostic of said disorder or skin damage.
  • the polypeptide may be detected by, for example, using the antibodies described hereinbefore.
  • the sample and animal is preferably as described herein.
  • the amount is preferably a reduction in the level of said polypeptide compared to normal levels. Diagnosis may be achieved by comparison to standard tables of normal subjects compared to those with the disorder or skin damage under investigation.
  • polypeptides or nucleic acid molecules used in compositions and uses of the invention as described hereinbelow may be obtained or derived from naturally occurring sources or may be generated entirely or partially synthetically.
  • polypeptides and nucleic acid molecules are isolated in accordance with the protocols described in the Examples.
  • polypeptide of the invention When the polypeptide of the invention is obtained from leukocytes it is obtained in unmodified form. Polypeptides obtained from salmon hatching fluid are modified (by glycosylation and/or phosphorylation), but both forms are equally effective in the methods described herein.
  • the polypeptides or nucleic acid molecules described herein are preferably substantially free of any contaminating components derived from the source material or materials used in the isolation procedure or in their synthetic preparation.
  • the compound is purified to a degree of purity of more than 50 or 60 %, e.g. >70, 80 or 90%, preferably more than 95 or 99% purity as assessed w/w (dry weight).
  • purity levels correspond to the specific molecule of interest, but includes its degradation products.
  • enriched preparations may be used which have lower purity, e.g. contain more than 1, 2, 5 or 10% of the malecule of interest, e.g. more than 20 or 30%.
  • the polypeptides of the invention may be purified by, for example, chromatography (e.g. HPLC, size-exclusion, ionexchange, affinity, hydrophobic interaction, reverse-phase) or capillary electrophoresis.
  • Polypeptides of the invention may be generated synthetically, e.g. by ligation of smaller synthetically generated peptides or more conveniently by recombinant expression of a nucleic acid molecule encoding said polypeptide as described hereinbefore.
  • Nucleic acid molecules of the invention may be generated synthetically, e.g. by amplification of a nucleic acid sequence as described herein such as from an appropriate cDNA library.
  • polypeptides, nucleic acid molecules or antibodies as described herein may be used in vitro, for example in cell or organ culture, to affect immune functions in cells.
  • polypeptides, nucleic acid molecules or antibodies may be used ex vivo, on animal parts or products, for example organs or collected blood, cells or tissues, particularly when it is contemplated that these will be reintroduced into the body from which they are derived.
  • polypeptides are preferred for use in vivo as discussed in more detail below.
  • Polypeptides, nucleic acid molecules and antibodies as described herein have applications for the treatment of various disorders or conditions as described hereinafter.
  • the present invention thus extends to a pharmaceutical composition comprising a polypeptide, nucleic acid molecule or antibody as described hereinbefore and one or more pharmaceutically acceptable excipients and/or diluents.
  • pharmaceutically acceptable or “physiologically acceptable” is meant that the ingredient must be compatible with other ingredients in the composition as well as physiologically acceptable to the recipient.
  • the active ingredient for administration may be appropriately modified for use in a pharmaceutical composition.
  • the compounds used in accordance with the invention may be stabilized against degradation by the use of derivatives as described above.
  • the active ingredient may also be stabilized in the compositions for example by the use of appropriate additives such as salts or non-electrolytes, acetate, SDS, EDTA, citrate or acetate buffers, mannitol, glycine, HSA or polysorbate.
  • appropriate additives such as salts or non-electrolytes, acetate, SDS, EDTA, citrate or acetate buffers, mannitol, glycine, HSA or polysorbate.
  • nucleic acid molecule, polypeptide or antibody of the invention may be present in said compositions as the sole active ingredient or may be combined with other ingredients, particularly other active ingredients, e.g. to augment the therapeutic effect or to make the composition more appealing to the consumer.
  • composition comprising the polypeptide of the invention may also comprise zonase or a related enzyme.
  • zonase is a preparation containing an enzyme, wherein said preparation exhibits one protein band on SDS-PAGE analysis, with a molecular weight of around 28kDa, obtainable by a method comprising the steps of:
  • Zonase may be prepared as described in the examples and added to the composition or may represent an "impurity" after the preparation of the polypeptide of the invention from natural sources.
  • the polypeptide may be present in the range 1-100% of their total combined weight and zonase may make up 0 to 99%.
  • the polypeptide is present at a range of 50-100%, e.g. >80, 90, 95, 96, 97, 98 or 99 and zonase is present at 0 to 50%, e.g. ⁇ 20, 10, 5, 4, 3, 2 or 1% of the combined weight.
  • composition comprising:
  • the polypeptides and nucleic acid molecules of the invention exhibit therapeutic properties in the treatment of various autoimmune and inflammatory disorders, particularly of the skin as well as treatment of damaged skin, e.g. by sun, cold, irradiation (e.g. X-ray, such as when used to treat cancers) or as a result of a wound.
  • irradiation e.g. X-ray, such as when used to treat cancers
  • a "disorder” refers to an underlying pathological disturbance in a symptomatic or asymptomatic organism relative to a normal organism, which may result, for example, from infection or an acquired or congenital genetic imperfection.
  • leukolectin for treating a variety of inflammatory, autoimmune and other skin conditions has been illustrated. Similar efficacy may be expected for treating other conditions. For example, chronic gastrointestinal inflammation may be explained by an excessive reaction to (or perhaps in some instances as) failure of reaction by dendritic cells to noxious agents. The introduction of leukolectin, e.g. orally, would therefore be expected to treat the chronic GIT inflammation in much the same way that inflamed skin responds favourably to the introduction of leukolectin.
  • Autoimmune diseases may stem from specific somatic expression of mutated versions of normal cell-surface antigens.
  • leukolectins may serve to protect target cells from attack.
  • an "inflammatory disorder” is a disorder in which inflammation is observed at some point during the disorder's progression and may be the sole symptom or one of several symptoms.
  • the inflammatory disorder may be acute or chronic and may be as described hereinbefore or hereinafter.
  • Inflammatory disorders include cardiovascular inflammation (e.g. atherosclerosis, stroke), gastrointestinal inflammation (including ulcers such as gastric or duodenal ulcers), hepatic inflammatory disorders, pulmonary inflammation (e.g.
  • asthma ventilator induced lung injury
  • kidney inflammation ocular inflammation (e.g., uveitis), pancreatic inflammation, genitourinary inflammation
  • neuroinflammatory disorders e.g., multiple sclerosis, Alzheimer's disease
  • allergy e.g., allergic rhinitis/sinusitis
  • skin allergies and disorders e.g., urticaria/hives, angioedema, atopic dermatitis, contact dermatitis, psoriasis
  • food allergies e.g., drug allergies, insect allergies, mastocytosis
  • skeletal inflammation e.g., arthritis, osteoarthritis, rheumatoid arthritis, spondyloarthropathies
  • infection e.g., bacterial or viral infections
  • oral inflammatory disorders i.e. perodontis, gingivitis or somatitis
  • transplantation e.g., allograft or xeno
  • Inflammatory disorders for treatment according to the present invention are inflammatory skin disorders such as Eczema, Acne, Rosacea, psoriasis and contact dermatitis, gastrointestinal inflammation and conditions of the mucous membranes such as ulcers or sores.
  • an "autoimmune disorder” is one in which benign autoimmunity has progressed to pathogenic autoimmunity and may be as described hereinbefore or hereinafter.
  • Autoimmune diseases include, Acquired Immunodeficiency Syndrome (AIDS, which is a viral disease with an autoimmune component), alopecia areata, ankylosing spondylitis, antiphospholipid syndrome, autoimmune Addison's disease, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune inner ear disease (AIED), autoimmune lymphoproliferative syndrome (ALPS), autoimmune thrombocytopenic purpura (ATP), Behcet's disease, cardiomyopathy, celiac sprue-dermatitis hepetiformis; chronic fatigue immune dysfunction syndrome (CFIDS), chronic inflammatory demyelinating polyneuropathy (CIPD), cicatricial pemphigoid, cold agglutinin disease, crest syndrome, Crohn's disease, Degos' disease,
  • “Damaged skin” as referred to herein includes skin which has been damaged by external influences such as heat, irradiation (by light of various wavelengths such as X-ray or UV), cold, friction, tearing or a wound, e.g. resulting from an accident or surgery.
  • damaged skin may result from an infection, or disease or underlying genetic abnormality. The damage may be exhibited as cracks, redness, itching, inflammation, horny skin, flakes, etc.
  • the present invention provides the use of:
  • the invention provides:
  • the invention provides such uses, polypeptides, nucleic acid molecules, or pharmaceutical compositions for topical administration to the skin.
  • said disorder is eczema, acne, psoriasis, gastrointestinal inflammation (such as in Crohn's disease, ulcerous colitis and other chronic inflammation), gingivitis and inflammation of the oral cavity and oesophagus and said damaged skin is irritated or inflamed, cracked by cold, sunburned, heat or irradiation damaged or as the result of a wound.
  • treating refers to the reduction, alleviation or elimination, preferably to normal levels, of one or more of the symptoms or effects of said disorder or damage e.g. presence or extent of damaged skin, e.g. relative size of the wound, inflammation, redness, itching, pain etc. relative to the symptoms or effects present on a different part of the body of said individual not subject to said treatment or in a corresponding individual not subject to said treatment.
  • Preventing refers to absolute prevention, or reduction or alleviation of the extent or timing (e.g. delaying) of the onset of that symptom or effect. This may be achieved, for example, by gene therapy methods, e.g. use of anti-RNA or non-sense sequences.
  • compositions of the invention may advantageously be combined with administration of one or more active ingredients which are effective in treating or preventing the disorders or skin damage.
  • pharmaceutical compositions of the invention may additionally contain one or more of such active ingredients.
  • compositions of the invention may be formulated in conventional manner with one or more physiologically acceptable carriers, excipients and/or diluents, according to techniques well known in the art using readily available ingredients.
  • the active ingredient may be incorporated, optionally together with other active substances as a combined preparation, with one or more conventional carriers, diluents and/or excipients, to produce conventional galenic preparations such as tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions (as injection or infusion fluids), emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments, soft and hard gelatin capsules, suppositories, sterile injectable solutions, sterile packaged powders, and the like.
  • Biodegradable polymers such as polyesters, polyanhydrides, polylactic acid, or polyglycolic acid
  • the compositions may be stabilized by use of freeze-drying, undercooling or Permazyme.
  • Suitable excipients, carriers or diluents are lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, calcium carbonate, calcium lactose, corn starch, aglinates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water syrup, water, water/ethanol, water/glycol, water/polyethylene, glycol, propylene glycol, methyl cellulose, methylhydroxybenzoates, propyl hydroxybenzoates, talc, magnesium stearate, mineral oil or fatty substances such as hard fat or suitable mixtures thereof.
  • Agents for obtaining sustained release formulations such as carboxypolymethylene, carboxymethyl cellulose, cellulose acetate phthalate, or polyvinylacetate may also be used.
  • compositions may additionally include lubricating agents, wetting agents, emulsifying agents, viscosity increasing agents, granulating agents, disintegrating agents, binding agents, osmotic active agents, suspending agents, preserving agents, sweetening agents, flavouring agents, adsorption enhancers (e.g. surface penetrating agents or for nasal delivery, e.g.
  • bile salts bile salts, lecithins, surfactants, fatty acids, chelators), browning agents, organic solvent, antioxidant, stabilizing agents, emollients, silicone, alpha-hydroxy acid, demulcent, anti-foaming agent, moisturizing agent, vitamin, fragrance, ionic or non-ionic thickeners, surfactants, filler, ionic or non-ionic thickener, sequestrant, polymer, propellant, alkalinizing or acidifying agent, opacifier, colouring agents and fatty compounds and the like.
  • compositions of the invention may be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the body by employing techniques well known in the art.
  • the composition may be in any appropriate dosage form to allow delivery or for targetting particular cells or tissues, e.g. as an emulsion or in liposomes, niosomes, microspheres, nanoparticles or the like with which the active ingredient may be absorbed, adsorbed, incorporated or bound. This can effectively convert the product to an insoluble form.
  • These particulate forms may overcome both stability (e.g. degradation) and delivery problems.
  • These particles may carry appropriate surface molecules to improve circulation time (e.g. serum components, surfactants, polyoxamine908, PEG etc.) or moieties for site-specific targeting, such as ligands to particular cell borne receptors.
  • appropriate surface molecules e.g. serum components, surfactants, polyoxamine908, PEG etc.
  • moieties for site-specific targeting such as ligands to particular cell borne receptors.
  • Appropriate techniques for drug delivery and for targeting are well known in the art and are described in WO99/62315 .
  • the active ingredient may be carried in water, a gas, a water-based liquid, an oil, a gel, an emulsion, an oil-in water or water-in-oil emulsion, a dispersion or a mixture thereof.
  • Compositions may be for topical (e.g. to the skin), oral or parenteral administration, e.g. by injection.
  • leukolectin shows very little variation between different species. Indeed, it has been found to be invariant in a healthy human population and this would hence allow the use of leukolectin, e.g. by administration by injection into subjects, without triggering a humoral antibody response, in a similar manner to the protein insulin which is also invariant in the human population. Therefore, systemic therapy by injection of leukolectin may be used to treat the conditions described herein, particularly auto-immune disorders.
  • Topical compositions and administration are however preferred, and include gels, creams, ointments, sprays, lotions, salves, sticks, soaps, powders, films, aerosols, drops, foams, solutions, emulsions, suspensions, dispersions e.g. non-ionic vesicle dispersions, milks and any other conventional pharmaceutical forms in the art.
  • Ointments, gels and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents.
  • Lotions may be formulated with an aqueous or oily base and will, in general, also contain one or more emulsifying, dispersing, suspending, thickening or colouring agents.
  • Powders may be formed with the aid of any suitable powder base.
  • Drops and solutions may be formulated with an aqueous or non-aqueous base also comprising one or more dispersing, solubilising or suspending agents. Aerosol sprays are conveniently delivered from pressurised packs, with the use of a suitable propellant.
  • compositions may be provided in a form adapted for oral or parenteral administration.
  • Alternative pharmaceutical forms thus include plain or coated tablets, capsules, suspensions and solutions containing the active component optionally together with one or more inert conventional carriers and/or diluents, e.g. with corn starch, lactose, sucrose, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, water/ethanol, water/glycerol, water/sorbitol, water/polyethylene glycol, propylene glycol, stearyl alcohol, carboxymethylcellulose or fatty substances such as hard fat or suitable mixtures thereof.
  • inert conventional carriers and/or diluents e.g. with corn starch, lactose, sucrose, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, water, water/ethanol, water/glycerol, water/sorbitol
  • concentration of active ingredient in compositions of the invention depends upon the nature of the compound used (i.e. the polypeptide, nucleic acid molecule or antibody), the mode of administration, the course of treatment, the age and weight of the patient, the medical indication, the body or body area to be treated and may be varied or adjusted according to choice. Generally however, concentration ranges for the compound described herein is 0.0001, 0.0005, 0.001 or 0.01 to 25%, e.g. 0.0005-15%, e.g. 0.01 to 10%, such as 0.1 to 5, e.g. 1-5% (w/w of the final preparation for administration, particularly for topical administration). Said concentrations are determined by reference to the amount of the compound itself and thus appropriate allowances should be made to take into account the purity of the composition.
  • Effective single doses may lie in the range of from 0.1-100mg/day, preferably 2-10mg/day, depending on the animal being treated, taken as a single dose.
  • the administration may be by any suitable method known in the medicinal arts, including for example oral, parenteral (e.g. intramuscular, subcutaneous, intraperitoneal or intravenous), percutaneous, buccal, rectal or topical administration or administration by inhalation.
  • parenteral e.g. intramuscular, subcutaneous, intraperitoneal or intravenous
  • percutaneous buccal
  • rectal topical administration or administration by inhalation.
  • the preferred administration forms will be administered orally, or most preferably topically.
  • oral administration has its limitations if the active ingredient is digestible. To overcome such problems, ingredients may be stabilized as mentioned previously.
  • the active ingredient for performance of the invention takes a variety of forms, e.g. nucleic acid molecule (which may be in a vector) or polypeptide, the form of the composition and route of delivery will vary. Preferably however liquid solutions, creams or suspensions would be employed, particularly e.g. for oral delivery or topical administration.
  • Either the polypeptide or nucleic acid molecules of the invention may be used for the above mentioned medical indications.
  • the nucleic acid molecules are preferably provided in vectors which are suitable for transfection/transformation as described above, e.g. viral vectors such as adenovirus using gene therapy methods known in the art for medical applications.
  • Animals to which the compositions may be applied or administered include mammals, reptiles, birds, insects and fish (e.g. salmon or cod).
  • animals to which the compositions of the invention are applied are mammals, particularly primates, domestic animals, livestock and laboratory animals.
  • preferred animals include mice, rats, rabbits, guinea pigs, cats, dogs, monkeys, pigs, cows, goats, sheep and horses.
  • the compositions are applied, or administered, to humans.
  • a method for preparing partially purified zonase which may be used as the starting material for isolating the polypeptide of the invention is provided in WO99/29836 (particularly Example 1 of the described method, but optionally without the urea step).
  • Both zonase and leukolectin were purified from salmon hatching fluid.
  • salmon eggs were transferred to minimal volumes of water prior to hatching.
  • Highly synchronous hatching can be induced by elevated (room) temperatures, or by deoxygenation ( Oppen-Berntsen et al. 1990, Aquaculture, 86, pp. 417-430 ), which yields a small volume of highly concentrated preparation of crude zonase and associated proteins.
  • the initial purification of zonase involved filtration of hatched salmon eggs through cheese cloth. This filtrate may be frozen for years without significant zonase degradation, before being thawed and employed for further protein purification. This fact greatly simplifies production of a starting material for purifying salmon zonase and associated proteins, including leukolectin.
  • the next, optional, step involved adjusting the protein filtrate to 4M urea, to dissociate fragments of the salmon eggshell, which allowed their removal along with extraneous debris by low speed centrifugation (15,000g; 2 x 15 min).
  • This material showed no sign of clogging columns, which is characteristic of crude materials prepared differently from what is described above.
  • This crude protein preparation was suitable for purification by conventional chromatographic techniques and zonase may be purified further as described in Example 7.
  • Leukolectin from hatching fluid may be isolated together with zonase.
  • leukolectin may be isolated by exclusion chromatography as zonase in its native form is substantially larger than Leukolectin.
  • ultrafiltration is also suitable as zonase in its native form does not significantly penetrate ultra filters with size exclusion of 100 kDa unlike leukolectin.
  • Buffers used are millimolar Tris (e.g. 10 mM)at pH around neutrality or slightly alkaline (pH 7.5 - 8.5), containing 5 mM NaCl.
  • the isolated protein was also found to be expressed in gametes and in the zygote, and furthermore, also in the early embryo (during ontogeny of the hemopoietic system), and finally, in leukocytes.
  • the isolated protein was used to generate a polyclonal antibody.
  • Cells were analysed for the presence of the protein by means of a rabbit polyclonal anti-LL antibody using an immunoperoxidase staining method or indirect immunofluorescence. The results are shown in Figure 2 .
  • the new protein originated in a cell type different from the cells that produce choriolysins (hatching enzymes).
  • the morphology of these individual cells is shown in the Figure and is clearly distinct from (individual) hatching gland cells expressing choriolysins.
  • the new protein was subjected to standard characterization such as determination of its tryptic peptides, followed by partial direct Edman sequencing. From the puzzle of peptides, trial and error constructions of degenerate primers for detecting an mRNA in fish embryos to produce a cDNA, were at first unsuccessful until the reverse primer was set simply to match a polyA-tail. In this manner, and with the use of multiple new primer sets as they became identified, we were able to find at least two cDNAs of approximately 1200 NT. These proved to be very similar in sequence, with only a handful of variant AA residues. For both, some of the N-terminal sequence was missing.
  • N-RACE methodology we subsequently established that the above sequences belonged to a protein of 255 amino acids, with a 19 AA propeptide and with an unusual N-terminal tryptophan residue in the processed protein. This latter result would explain the great difficulties in obtaining an N-terminal sequence by direct analysis. However, this was eventually achieved to confirm the virtual N-terminal residues.
  • the propeptide form of the new lectin contains a 19 AA peptide which suggested its targeting to lysosomes and for later potential secretion (i.e. into the perivitelline space).
  • the virtual AA-sequence of the new lectin allowed the development of epitope-specific antibodies, which in turn allowed us to identify many (2 - 8) seeming isoforms of the protein ( Fig. 5 ), depending on tissue analyzed.
  • Lectin found in the hatching gland cells ( Fig. 6B ) is secreted into the perivitelline space along with the choriolysins, and that these possess posttranslational modifications which increase their apparent size and which lower their apparent pI.
  • the array of 8 Leukolectin moieties in partially purified zonase preparations may stem from three increasing modifications of two slightly different Leukolectin proteins, for a total of 4 x 2, or 8 differing leukolectins. The causes of variation need to be empirically verified.
  • the estimated MW of the lectin is around 25-30 kDa.
  • nucleotide probes to locate the expression of the new protein during fish embryonic development, we found the protein present in specific types of epidermal cells of fish embryos. Additionally, we found expression of the protein in both gametes as well as in the zygote. Furthermore, the protein was shown to be absent in most cells of the organisms, but expressed in a few embryonic cells which suggested that the protein could be tied to myelopoiesis ( Figs. 5 and 6 ). Such an expression pattern is unique. Thus, we chose the name "leukolectin” (abbreviated LL) for the protein.
  • LL myelopoiesis
  • leukolectins are present in leukocytes throughout this vertebrate lineage. Its presence could also be detected in whole invertebrates using our polyclonal antibody. Finding leukolectins in (human) leukocytes immediately suggested possible functions for leukolectins. Leukolectin occurs in cells carrying out immune functions.
  • LL-family of proteins The summary of variant LL structure ( Fig. 7 ) defines the new LL-family of proteins. We see about 2 % non-conservative changes in AA from fish to humans. Clearly, LL-genes code for proteins which are subjected to extreme evolutionary selection in order to maintain sequence invariability. This in turn points to important, but as yet unknown functions that prevent most random variation in the gene products from arising and taking hold during species evolution.
  • cDNA of salmon Leukolectin was cloned from embryos.
  • the PCR primers were designed to contain the NcoI restriction site (forward) and ACC65 I (reverse).
  • Vector pETM-60 were digested with NcoI/ACC65I and digested PCR products were ligated by overnight -ligation.
  • Bacterial culture and protein purification The new bacterial vector pETM60-Leukolectin enabled the expression of His-tagged recombinant proteins fused to the C-terminus of NusA through a TEV protease recognition sequence. They were efficiently purified by metal affinity and recovered in soluble form after the removal of the fusion partner.
  • Both PCR product and pETM-60 plasmid were digested with NcoI and ACC65I restriction enzymes; and purified from 1% agarose gel for ligation.
  • T4 ligase was used to join the 5' phosphate and the 3'-hydroxyl groups of double stranded DNA molecules using the following mix:
  • the ligation mix was electroporated in DH5 ⁇ competent cells, and the colonies used to inoculate 5 ml of LB.
  • BL21(DE3)pLysS contains a plasmid (pLysS with chloramphenicol resistance) that encodes T7 lysozyme to reduce background levels of T7 polymerase prior to induction.
  • BL21(DE3)pLysS provides tighter control of protein expression of toxic proteins and is a strain for high-level protein expression and easy induction.
  • the fusion tag used in the recombinant protein expression and purification was NusA which has a 495aa (54.81kDa) size and is located at the N-terminus and is used to enhance solution of proteins that are overexpressed.
  • NusA-Leukolectin was efficiently purified by metal affinity and recovered in soluble form after the removal of the fusion partner.
  • the column was washed with 75 ml buffer B. Elution was with 25 ml buffer C (1xPBS, 0.5 M imidazole, 0.4 M NaCl), with a one step elution. 1 ml samples were collected.
  • Recombinant leukolectin is devoid of serine protease activity, and is thus a true lectin.
  • traces of serine protease activity found in some leukolectin preparations from natural source must therefore represent traces of zonase.
  • Leukolectin and Zonase co-exist in hatching fluid, and tend to co-purify during most chromatographic procedures, but may be separated by final ultrafiltration using 100 kDa exclusion size Biomax filters.
  • Recombinant salmon LL produced as above and purified by SDS PAGE was analyzed by MS/MS techniques.
  • LL's Peptide Mass Fingerprint spectrum was analyzed in Mascot both in NCBI protein and EST databases for Actinopterygii without finding any significant hits (Riste, unpublished). These spectra compared well with LL spectra obtained from embryonic and leukocytic LL moieties eluted from 2D-gel analysis of such LLs, further confirming the existence of isoforms of LL observed by pH-gradient methods.
  • Lectin gene-specific probes were used to screen a BAC library (18x coverage; average insert size, 188 kb), which was made available by the Salmon Genome Project (SGP) consortium. Probes (size 630 bp) were prepared by incorporating digoxigenin-11-dUTP (Roche) using the PCR method. Screening of the Bac library resulted in the identification of 7 positive clones characterized as A-12/144, L16 /143, P6/76, B-5/70, O-20/85, L-7/257, F-7/176. Positive responses are exemplified in Panels A&B.
  • leukolectins appear as normal genes with 5 exons and 4 introns, in a gene about 2300 bp from transcription start to the polyadenylation site, a fairly standard size.
  • Transgelin is a smooth muscle protein 22-alpha (SM22-alpha) (WS3-10).
  • Transgelin is an actin-binding protein, and is one of the earliest markers of differentiated smooth muscle. The function of this protein has not yet been determined. http://harvester.embl.de/harvester/P378/P37802.htm
  • the observed pattern of distribution on chromosomes is baffling. Such short sequences may not be related to the LL- gene, if the human LL-gene itself until now has not been sequenced or located to a specific chromosome. The resolution of this conundrum is as yet not at hand.
  • a new LL-lectin has been identified in human leukocyte which is nearly identical to LL from fish and chicken.
  • the LL gene in salmon is of standard structure but is not yet found in humans.
  • Example 2 Medical applications of leukolectin
  • LL salmon leukolectin protein
  • LL-concentration used was ca. 1-10 microgram/ml.
  • Zonase-protease was present with LL in a ratio of 1:100 in a water and coconut oil emulsion (in which over 30 % coconut oil is present).
  • Leukolectin is stable in the presence of zonase.
  • Sub-clinical cases of acne have responded in many juveniles by an immediate cessation of itching and of redness. Improvement of acnes per se has been seen in a small pilot study in about half of the cases upon application of LL in the coconut oil emulsion.
  • Differentiated human skin epithelium cultures were obtained from SkinEthics (Nice, France) at day 16 after seeding onto plastic growth substrata with micropores allowing nutrients access to the epithelial tissue from below. Such cultures exhibit normal skin morphology after differentiation during the culturing period at 37°C. These cultures were maintained for two more days in vitro so that the upper stratum corneum was exposed to air, and stratum basalis to the growth substratum. Parallel cultures were moved to 30°C moist atmosphere and presented with a medium Ca, Mg-containing phosphate-buffered saline for 6 hours with or without the presence of 10 ⁇ g/ml of salmon leukolectin.
  • dendritic cells are the only cells in the epithelial skin related to blood leukocytes. Normal access of leukocytes to the epithelial skin is interfered with after some mechanical or biological insult due to poor circulation, which is where compression wounds often occur in the normal skin. Administration of leukolectin overrides this deficiency and triggers normal mechanisms of healing in the skin.
  • Salmon blood was obtained from Industrilab, Univ. of Bergen. Whole fish blood was collected in heparinised tubes (Riste, unpublished), and processed according to Miller et al. (1988, Nucleic Acids Research, 16(3) p1215 ). Human blood samples were obtained from the Blood Bank at Haukeland University Hospital, Norway.
  • the LL proteins from these two species were visualized by 2D PAGE using immunoblots for specific detection of LL proteins and their isoforms. Treatments with polyclonal primary antibody to salmon LL followed by goat anti-rabbit antibody, allowed visualizing LL-proteins by ECL-enhanced detection system. The specificity of the immunoreaction was tested in multiple gels applying from 0.5-5 ⁇ g of protein, with similar results.
  • Salmon leukocytes exhibit 2 LL-isoforms of MW ⁇ 26 kDa, with pI similar to the more basic forms of the 8 LL isoelectric forms found in salmon PVF. It is difficult to estimate exact MWs by extrapolation from MW standards in the second dimension of 2D PAGE. Human leukocytes contain one main LL-antigen of molecular weight ⁇ 30 kDa, which from other observations is close to 27 kDa. The acidic pI corresponds to the average pI of salmon LL-isoforms found in PVF (Riste, supra ) (see Figure 12 ).
  • Salmon eggs were obtained from a farmed salmon broodstock at Bolaks as (Fusa, Norway), maintained for multiple generations since 1975 by phenotypic selection, and now part of the salmon stock propagated by Salmo Breed A/S, Norway.
  • DIG Antisense Digoxigenin labelled cRNA probe was generated by transcription of SP1 digested plasmid DNA templates with T3 RNA polymerase.
  • Sense DIG-labelled cRNA probe was generated by transcription ofXhoI digested plasmid DNA template with T7 RNA polymerase (sense) using DIG RNA Labelling Kit (SP6/T7) (Roche Diagnostics) according to manufacturer's protocols.
  • the digoxigenin (DIG)-labeled LL antisense and sense cRNA probes generated spanned ⁇ 650 bp.
  • the membranes were incubated in a blocking solution containing maleic acid buffer (pH 7.5) and 1% blocking reagent (Roche) and subsequently in the blocking solution with anti-DIG-alkaline phosphatase (AP) conjugated antibody (Roche) diluted 1:10,000 at RT for 1 h. After washing with 100 mM maleic acid buffer (pH 7.5) containing 150 mM NaCl and 0.5 % Tween 20, the membrane was equilibrated 2 min in detection buffer (0.1 M TrisHCl, 0.1 M NaCl, pH 9.5 at RT).
  • detection buffer 0.1 M TrisHCl, 0.1 M NaCl, pH 9.5 at RT.
  • Hybrid probe targets were visualised by chemiluminescent assay using CSPD (Roche) as a substrate, and exposure of the blots to X-ray film (Kodak) for 5-30 min. DIG-labelled RNA molecular weight marker (Roche) was used.
  • Antisense DIG labelled LL specific riboprobe was used to estimate the size of mature LL transcripts.
  • Northern blot analysis of total RNA revealed a major transcript with the size ⁇ 1250 bp, and also a weaker band transcript ( ⁇ 3200 bp) was observed. The dominant band corresponds to a transcript of the mature (intron-less) and translatable LL transcript.
  • Northern blot analysis of purified mRNA using the same riboprobe revealed a single band of ⁇ 1250 bp (indicating that the amplified cDNA was close to a full length coding sequence ( Figure 13B ).
  • Example 5 Alignment of LL with related ⁇ -propeller proteins
  • Bioinformatic analyses were carried out on salmon LL sequences compared to information deposited in public sequence banks.
  • the first bridge connects the N-terminal end to the C-terminal end of both proteins.
  • the bridge connects cysteines at positions 3 and 234 in LL (or 238 in FEL)).
  • the second and third bridges connect Cys 102 to Cys 155 in LL (#157 in FEL), and Cys 132 and Cys 137 in both LL and FEL.
  • the fourth disulphide bond found in carp FEL, involving Cys 208 (212) and Cys 226 (230) is not found in leukolectin.
  • the leukolectin protein shares a high degree of similarity in terms of TECPR domain architecture with L6 or tachylectin 1 ( Tachypleus tridentaus ), a bacterial lipopolysaccharide-binding lectin from horseshoe crab hemocytes, and other invertebrate tachylectin-related proteins. Nevertheless, differences in terms of the number of domains, along with a slight shift of the ⁇ -propeller domains toward the C-terminal of the protein, were observed. Summarizing the information from similarity searches and the SMART searches, we infer that the overall 3-D structure of the leukolectin exhibits a 5-bladed ⁇ -propeller protein structure.
  • the salmon hatching fluid in Example 1 may be further purified to yield a pure zonase preparation.
  • One round of gel filtration was sufficient to separate zonase from the larger molecular components in the filtrate with a 12 fold purification with better than a 50% yield.
  • the matrix utilized may vary, but Sephacryl SR-200® was our usual choice.
  • the buffer was Tris-HCl pH 8.0 or pH 8.5 (0.05 M) or Tris-Acetate (0.025 M, same pHs).
  • the zonase obtained after gel filtration procedures accounted for the predominant zonase moieties in the hatching fluid.
  • Zonase was purified to a homogeneous protein product by affinity chromatography on commercially available Benzamidine Sepharose 6B®-columns.
  • the specific conditions utilized (with columns of 25 or 125 ml volumes) was again a 0.05 M Tris-HCl buffer (pH 8 or 8.5), which for removing non-specifically bound material on the columns, was adjusted to 1 M NaCl.
  • Zonase was not removed by this step, as the protein remained tightly bound to the column.
  • Elution of zonase from the column was achieved by using a 10-33 % dioxane-gradient in 1 M NaCl in the same Tris-HCl buffer.
  • affinity-purification the zonase preparation exhibited one protein band on SDS-PAGE analysis, with a molecular weight of around 28kDa. Whilst, this zonase product was not of sequence-grade purity it was highly purified.
  • Gel filtration-purified plus affinity-purified zonase was further purified to sequence-grade purity by one final chromatographic procedure.
  • This procedure employed a PBE94® column, with a buffer of Tris-Acetate (10 mM, pH 9.0), where subsequent elution was with a salt gradient (up to 1 M NaCl salt) in this buffer.
  • This step itself increased the catalytic activity of the zonase by a further 7.6 fold, for an overall purification of 714 fold, and with a yield of 28 % from the starting material.
  • This purification step left the protein identity of the zonase intact as a 28 kDa moiety.
  • Polyclonal rabbit anti-rabbit anti-salmon LL antiserum was prepared as follows: Sequence grade purified leukolectin protein from Example 1 was used for raising polyclonal antibody in 4 kg Chinchilla rabbit, as described by Harlow and Lane (1988, Laboratory Manual, Cold Spring Harbor, NY ). Three injections of 80, 40 and 25 mg of sequence-grade leukolectin were placed in multiple subcutaneous sites. The first was emulsified with Freund's complete adjuvant, the last two with incomplete adjuvant after 3 and 6 weeks. Eight days after the final booster, blood was collected and serum prepared after centrifugation at 3,000 rpm (Sorvall SS-34 rotor) for 15 min.
  • IgG fraction was eluted with 5 ml of elution buffer (0.1 M glycineHCl, pH 2.7) and divided into 10 tubes containing 25 ⁇ l of neutralisation buffer (1 M TrisHCl, pH 9.0). Concentration was determined spectrophotometrically. Purity was estimated by analysing the aliquots of purified IgG fractions in 12% SDS-PAGE with subsequent silver staining. Sensitivity was determined by Western blot analysis using goat anti-rabbit IgG, horse radish peroxidase conjugated secondary antibody.
  • polyclonal antibodies were preadsorbed by incubation in zebrafish acetone powder.
  • Fluorescein isothiocyanate (FITC)-labelled swine anti-rabbit F(ab')2 was from Dako (F-0054).
  • Alexa Fluor 647-labelled goat anti-rabbit IgG was obtained from Molecular Probe, Eugene, US (Invitrogen, catalog nr.A-21244) and biotinylated polyclonal swine anti-rabbit immunoglobulins was from Dako (catalog nr.E0353).
  • the optimal concentrations of the primary and secondary antibodies were determined by prior dilution experiments.
  • the polyclonal antibodies were used in the protein expression analysis described in Example 1.
  • Reverse transcription was performed using 200 U/ ⁇ l TermoScript (Invitrogen). mRNA (0.5 ⁇ g) was heated to 72°C for 5min, cooled, pelleted and added to a 20 ⁇ l reaction mixture containing 100 ng/ ⁇ l oligo dT, 10 ⁇ M DDT, and 0.8 U/ ⁇ l RNAse Inhibitor in 2.0 mM cDNA synthesis buffer (Invitrogen). Incubation was at 50°C for 1 h. Products were purified by phenol/chloroform/ isoamyl alcohol extraction, passed through MicroSpin S-200HR column, and ethanol-precipitated. Gene-specific LL primers were designed from salmon LL sequences (Table 3).
  • the PCR mix (20 ⁇ l) contained 2 ⁇ l of cDNA template, 0.4 ⁇ M of primers (LLF1, LLF2, LLR1, LLR2, and LLR3), 1x PCR buffer, 0.5 U Taq DNA polymerase (Takara), and 0.2 mM of dNTPs.
  • PCR amplification used 32 cycles of 94 °C for 45 s / 58°C for 45 s / 72°C for 90 s and final extension at 72°C for 7 min.
  • the reaction mixture was analysed by 1.8% agarose-TBE gel with 0.5 ⁇ g/ml ethidium bromide in 1x TBE buffer (pH 8.3) with DNA marker 100 bp ladder (New England Biolabs).
  • the PCR fragment was ligated into a pGEM T-Easy Vector system 1 (Promega, Madison, WI) by standard protocols.
  • Electroporation used 40 ⁇ L of E. coli DH5 ⁇ , and 1 ⁇ L of ligated PCR fragment in the pGEM T-Easy Vector. SOC medium (1 ml) was added before bacteria were incubated at 37 °C for 1 h. The recombinant bacteria (200 ⁇ L) were plated on standard LB/ampicillin, X-gal, IPTG agar plates and incubated at 37°C overnight for blue/white screening. Ten white clones were picked and grown in a 5mL overnight culture in LB medium with 100 ⁇ g/mL ampicillin. Plasmid purification used Plasmid Minipurification kit.(Qiagen, Chatsworth, CA). Plasmids were amplified and sequenced using standard protocols (DNA Sequence Lab, Bergen).
  • 5'- and 3'-RACE PCRs of LL were performed using the GeneRacer core kit (Invitrogen cat. #45-0168) according to instructions. 2 ⁇ g of total RNA was used to synthesize the first-strand cDNA in RT using Superscript III (Invitrogen). First round 5'- and 3'-RACE PCR amplification was performed applying 5'- or 3'-GeneRacer primer and reverse or forward gene specific primer LLR2 & LLF3 (Table 3). Nested 5'- or 3'-RACE PCR amplification employed nested 5'- or 3'-RACE PCR GeneRacer primer and nested reverse or forward gene specific primer LLR4 & LLF4.
  • first step five cycles, 94°C for 30 sec and 72°C for 1 min; next five cycles at 94°C for 30 sec and 70°C for 1 min; third step 30 cycles with 94°C for 30 sec, and 68°C for 45 sec and 72°C for 1 min; final extension step 72°C for 7 min.
  • Templates for nested PCR used PCR product from first round RACE PCR diluted 1:25 in distilled water.
  • Primers for RACE PCR are listed in Table 3.
  • Single PCR products were purified using PCR purification kit (Promega, Madison, WI, US), and ligated into PCR II Topo vector (Invitrogen) for transformation of JM109 high-efficiency competent E. coli (Invitrogen). Recombinant bacteria were identified by blue/white screening on Lucia Bertani agar plates. Plasmids containing the inserts were purified using Promega purification kit and sequenced with M13 primers. The LL mRNA sequence was analysed using the Blastx and Blastp search programs.
  • 5'-RACE PCR clarified the sequence of 5'-untranslated (5'-UTR) region of zebrafish LL.
  • First round of RACE PCR amplification yielded very weak products.
  • Such amplified products from all stages were used for second round RACE PCR using high annealing temperature (65°C) in order to increase the specificity of the reaction, using a 1:20 dilutions of the first RACE PCR reaction.
  • the same two products (520 and 420 bp) were generated from all stages ( Figure 16B ), even from 4 hpf.
  • LL-sequence information from more than 20 clones was obtained. All clones contained the 29 nts upstream region ( Figure 16C ) detected in salmon LL. The 3'-end was also sequenced by multiple analysis and revealed a structure very similar (almost identical) to the structure found in salmon leukolectin. Based on the full length cDNA sequence, the deduced zebrafish LL-protein was deposited in the NCBI Gene Bank (Acc.nr. FJ 643620). The encoding sequence consists of 1,213 nts with an open reading frame of 765 nucleotides.
  • the deduced amino acid sequence for zebrafish LL suggests a protein of 255 AAs, given a translation start codon at nt position +1 (or nts 30 - 32; ( Figure 16C ).
  • LL cDNA also has a potential start codon at nt +94 ( Figure 16C ).
  • the transcript contained the 29 nts upstream from the +1 site, but lacked the next 93 nts (the nt-sequence read correctly up till -1 followed by the nt at +94: Fig. 16C ).
  • the data suggest that two different LL-proteins may be translated ( Figure 16C ).
  • Zebrafish LL is a hybrid structure compared to the two salmon LLs. Of seven LL-classification criteria established, 4 criteria placed zebrafish LL in category LL-1, while 2 criteria placed it in category LL-2 ( Figure 16E ). The seventh criterion is unique for zebrafish LL ( Figure 16E , boxed area). Furthermore, one Cys is missing in exon 3 and replaced by Arg in the sequence "nmnTPYClts", which in zebrafish reads "nmnDTPRlts". In consequence, zebrafish LL has 5 cysteines, where salmon has 6 cysteines, all predicted in disulfide bridges.
  • exon 1 is identical, while zebrafish exon 2 has three unique AAs not found in salmon (Gly-Arg instead of Ser-Gln at positions # 57 & 58, and Val instead of Ile at position # 78). Exon 3 has 4 altered residues (or 2?). In exons 4 & 5 there are no differences apart from the 3 classification sites. Thus, there are 5 (or 7) unique AAs in zebrafish LL (255 AAs total), ignoring classification sites. Zebrafish LL is highly conserved compared to salmon LL, differing only by few percentage points.
  • Zebrafish LL ( Figure 16D,E ) is closely similar to salmon LL. Zebrafish LL lacks one of six Cys seen in salmon LL, and thus may contain only two disulfide bridges: one connecting the N- and C-terminals, plus an internal bridge in exon 4. Comparing salmon and large zebrafish LL ( Figure 16E ), the stereotypical structural variations seen in salmon are reinforced by the zebrafish LL structure. One radical difference is observed (residue # 131), but mostly conserved substitutions are seen where variations in salmon LL occur. In PVF, LL may have immunoprotective functions. Restricted variations in LL structure may relate to such functions.
  • tLL The truncated leukolectin (tLL) lacks the secretory peptide, suggesting that tLL ( Figure 16D ) is not secreted, and tLL may be a 4-bladed ⁇ -propeller protein. Different LL-proteins may in theory perform different cellular functions. The function of tLL may function in cells other than lectocytes.
  • a 620 bp LL-specific cDNA probe was prepared by incorporating digoxigenin-11-dUTP (Roche) by PCR method, using Forward primers LL/F 5'-TACGGACACAGGTCGAATCCCCTACTACC-3' and reverse primer LL/R 5'-ACAGAGAAGAGGCTAATGTGTGCAC-3'.
  • DIG-labelled cDNA probe was incubation at 95°C for 10 min. and immediately placed in the ice for 5 min before addition to the hybridisation buffer (5x SSC, 50% formamide, 0.02% SDS, 2% Blocking agent (Roche), DEPC-treated water).
  • Hybridization was carried out in hybridisation tubes at 55°C overnight.
  • Post-hybridisation washing step was performed twice at low stringency in 2x SSC with 0.1% SDS at RT for 15 min each, and twice at high stringency in 0.1x SSC with 0.1% SDS at 65°C for 20 min each.
  • the filters were incubated in a blocking solution containing Maleic acid buffer (pH 7.5) and 1% blocking reagent (Roche), and subsequently in blocking solution with anti-Dig-alkaline phosphatase (AP) conjugated antibody (Roche) diluted 1:10,000 for 1 h at RT.
  • AP anti-Dig-alkaline phosphatase conjugated antibody
  • BAC DNA was digested with Not I and analyzed by Pulse Field electrophoresis(PFGE)( Osoegawa et al., 1998, Genomics, 52, pp. 1-8 ). Low Range PFG Marker (New England Biolabs) and ⁇ -Hind III fragment (Takara) were used as DNA size markers.
  • PFGE Pulse Field electrophoresis
  • PCR reactions were carried out using purified BAC DNA as a template and gene specific primers. The PCR reactions were incubated at 95°C for 3 min, followed by 35 cycles at 95°C for 30 s, annealing at 54°C for 30 s, and extension at 72°C for 30 s with a final incubation at 72°C for 10 min. After thermocycling, 2 ⁇ l of each PCR reaction was analyzed on a 1.5% agarose gel.
  • the results of the above screen identified 7 specific clones named A-12/144, L-16/143, P-6/76, B-5/70, O-20/85, L-7/257 and F-7/176 according to the BAC library nomenclature.
  • the mean insert size of the genomic BAC clones was estimated from DNA purified from all selected BAC clones, which subsequently was digested with Not I restriction enzyme. The DNA digestion products containing vector were separated by pulse field gel electrophoresis and visualized by ethidium bromide stain. All BAC clones produced only two bands, showing that the vector (pTARBAC2.1) size was ⁇ 13 kbp (13,397 bp; Osoegawa et al., 1998, supra ).
  • the data from the genomic clone L7/247 suggested a genomic organization of leukolectin where the gene is composed of 5 exons interrupted by 4 introns, and spans -2.3kbp starting from the TATA-box.
  • the genomic LL sequences revealed a TATA box starting at position -81 (TATAAAA) from ATG start codon, indicating an 81 nt 5'UTR (untranslatable element) of the mRNA.
  • the stop codon TAG is located at approximately 1850 nt from ATG in the genomic sequence.
  • a 6 nt long polyadenylation signal AATAAA starts around position 2,250 from ATG.
  • the 3'UTR is a sequence about 400 nt long starting after the stop codon TAG.
  • the LL-gene size is estimated to at least ⁇ 2.3kbp by conventional definitions, with introns accounting for twice as much sequence as exons.
  • PCR primers were designed from the established genomic intron sequences, and used to amplify each exon from salmon embryonic DNA. These 5 exon sequences were derived by direct sequence analysis of amplicons, and all corresponded to the established genomic sequences.
  • the data support a genomic LL gene structure with 5 exons and 4 introns for one of the two described variants of leukolectin.
  • the N-terminal AA residue of secreted LL protein has been established to be tryptophan by direct Edman degradation of purified LL.
  • This Trp-residue occupies position # 20 from the N-Terminal methionine in the 255 AA precursor protein, and is preceded by amino acids # 18 (His) and # 19 (Ala).
  • a cleavage site is predicted between Ala and Trp for a processing protease, to generate the secreted LL protein.
  • Exon 1 (19 AAs) is 55 nt long, with the sequence MRATA - AVLLV - LCLLT-ISH(A) and stops at the first G of codon for Ala #19 residue preceding the N-terminal tryptophan of the secreted leukolectin.
  • the large R in bold italics signifies a variant AA in this position possibly tied to a Leukolectin-3 gene (see Figure 17 ).
  • the genomic gene sequence continues with the nucleotides GT to start intron 1.
  • Intron 1 ends with the nucleotides AG followed by exon II, which contains the last two bases (-CA) of the #19 Ala codon followed by the TGG codon for # 20 Trp, the N-terminal of leukolectin.
  • Intron 1 is 89 nt long.
  • the asterisk denotes a residue where alternative AAs are found either in the LL protein or in multiple sequences of LL cDNA (see Figure 17 ).
  • G* appears to vary in Leukolectin-1, while L* appears to vary in leukolectin-2.
  • Intron 2 is 186 nts long, ending in the nucleotides AG.
  • the amino acid sequence of Exon 3 reads: (G)LL* KQL DAGGE - QFIVG ANMN* D TPYCLTSSAT - VGYKG PGSPL- PWTGL PGAVK - YYSCG P* FGCW - AVNKN DDIYL - MS, where the residue #150 is S.
  • the sequence reads: RDGIT-ASKPE-GTGWS-NIPMG*-MLMGHVTYDL-GRLWV-VSKSAV-TMVCT-H, where an asterisk indicates micro-variation in this position in leukolectin-1. Letters in bold signify differences between leukolectin-1 and leukolectin-2. Letters in bold and italics signify the possiblity of the existence of leukolectin-3. These data are summarized in Figure 17 .
  • Example 11 Comparison of leukolectin-1 genomic sequence to leukolectin mRNA sequences
  • the genomic sequence from L-7/247 corresponds to leukolectin clones classified as leukolectin-1.
  • the other sequenced cDNAs termed leukolectin-2 differ at the seven positions indicated. In addition to these positions, there are indications of some further variations in AA. This may suggest additional micro-heterogeneity of the two classified cDNAs, but the data may suggest the existence of a third category of LL cDNA, since for instance in position #226, we do find a tyrosine residue in some clones which was never observed in any leukolectin-1 or leukolectin-2 cDNA ( Figure 17 ).
  • FIG. 17 A summary of observed variations is shown in Figure 17 .
  • the two types of leukolectins are characterized by respectively (E, I, Y, Y, K, A, V) versus (N, V, F, F, N, G, G) at the seven positions (# 88, 91, 101, 147, 158, 229, 230) of the deduced AA sequence for the mature leukolectin. These 7 positions unambiguously classify these two leukolectins, which in addition may exhibit micro-variations at stereotypical positions shown by asterisks in Figure 17 .
  • the hatching fluid of Rainbow trout ( Oncorhyncus mykiss ) , Cod and Oikopleura dioica was investigated for the presence of leukolectin proteins.
  • Protein from hatching fluid was prepared by affinity chromatography analysed by 15% SDS-PAGE. The gel was either silver stained to show the presence of a variety of proteins, or blotted and probed with a salmon leukolectin antibody. In each case a single protein of ⁇ 26kDa was detected, corresponding to the molecular weight of leukolectin (see Figures 18 (Rainbow trout), 19A (Cod) and 19B ( Oikopleura dioica )) .

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
EP09745090.2A 2008-10-29 2009-10-29 Leukolectins and uses thereof Active EP2358745B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0819883.0A GB0819883D0 (en) 2008-10-29 2008-10-29 Product and uses
PCT/GB2009/002569 WO2010049688A1 (en) 2008-10-29 2009-10-29 Leukolectins and uses thereof

Publications (2)

Publication Number Publication Date
EP2358745A1 EP2358745A1 (en) 2011-08-24
EP2358745B1 true EP2358745B1 (en) 2017-11-29

Family

ID=40134057

Family Applications (1)

Application Number Title Priority Date Filing Date
EP09745090.2A Active EP2358745B1 (en) 2008-10-29 2009-10-29 Leukolectins and uses thereof

Country Status (20)

Country Link
US (2) US9260498B2 (ko)
EP (1) EP2358745B1 (ko)
JP (1) JP5539372B2 (ko)
KR (1) KR101448573B1 (ko)
CN (1) CN102203127B (ko)
AU (1) AU2009309477B2 (ko)
BR (1) BRPI0920101B1 (ko)
CA (1) CA2741823C (ko)
CL (1) CL2011000947A1 (ko)
CY (1) CY1119930T1 (ko)
DK (1) DK2358745T3 (ko)
ES (1) ES2658966T3 (ko)
GB (1) GB0819883D0 (ko)
MX (1) MX2011004483A (ko)
NO (1) NO2358745T3 (ko)
NZ (1) NZ592911A (ko)
PT (1) PT2358745T (ko)
RU (1) RU2528860C2 (ko)
WO (1) WO2010049688A1 (ko)
ZA (1) ZA201103456B (ko)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201007202D0 (en) * 2010-04-29 2010-06-16 Walther Bernt T Product and uses
GB201110777D0 (en) * 2011-06-24 2011-08-10 Aqua Bio Technology Asa Methods and uses
GB201110783D0 (en) 2011-06-24 2011-08-10 Aqua Bio Technology Asa Methods and uses
EP3100717B1 (en) * 2012-01-23 2021-10-06 Restorsea, LLC Cosmetic containing a fish spawn protein isolate
US10500255B2 (en) * 2012-12-21 2019-12-10 Aqua Bio Technology Asa Cosmetic compositions from fish hatching fluid
GB201223330D0 (en) * 2012-12-21 2013-02-06 Aqua Bio Technology Asa Products, methods and uses
MX2016007617A (es) 2013-12-13 2016-10-04 Restorsea Llc Formulacion exfoliante para promover la retencion del cabello.
EP3142633A1 (en) 2014-05-16 2017-03-22 Restorsea, LLC Biphasic cosmetic
RU2658781C1 (ru) * 2017-12-28 2018-06-22 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Пептид, обладающий противоопухолевой активностью
EP3802582A4 (en) * 2018-06-07 2022-06-15 Palleon Pharmaceuticals Inc. MULTIMERIC PROTEINS FOR DETECTING A CARBOHYDRATE AND/OR TREATMENT OF A SIGLEC MEDIATED DISORDER
EP3989933A4 (en) * 2019-06-28 2024-02-28 Biome Solutions Inc COMPOSITIONS, METHODS AND APPLICATIONS OF SYNTHETIC SURFACTANT

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008140200A1 (en) * 2007-05-10 2008-11-20 Seon-Il Kim External compositions for the skin
WO2011135059A1 (en) * 2010-04-29 2011-11-03 Leukolect As Human leukolectins and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9219905D0 (en) 1992-09-19 1992-11-04 Univ Liverpool Lectins
WO1994011497A1 (en) * 1992-11-16 1994-05-26 Incyte Pharmaceuticals, Inc. Method of causing selective immunosuppression using hl-60-related lectins
NO314594B1 (no) * 1997-12-11 2003-04-14 Aqua Bio Technology As Ikke-selvdegraderende endoprotease, fremgangsmåte for fremstilling samt anvendelser av denne
JP2002516670A (ja) 1998-05-27 2002-06-11 ラウラス エイエス Ｐｋａシグナリング経路のタンパク質活性を変化させる方法
DE602004024041D1 (de) 2003-03-05 2009-12-24 Halozyme Inc Lösliches hyaluronidase-glycoprotein (shasegp), verfahren zu seiner herstellung, verwendungen und dieses enthaltende pharmazeutische zusammensetzungen
US7510850B2 (en) * 2005-11-10 2009-03-31 Carnegie Institution Of Washington Isolation of the mitotic spindle matrix and its methods of use
GB201110777D0 (en) * 2011-06-24 2011-08-10 Aqua Bio Technology Asa Methods and uses
GB201110783D0 (en) * 2011-06-24 2011-08-10 Aqua Bio Technology Asa Methods and uses
US10500255B2 (en) * 2012-12-21 2019-12-10 Aqua Bio Technology Asa Cosmetic compositions from fish hatching fluid
GB201223330D0 (en) * 2012-12-21 2013-02-06 Aqua Bio Technology Asa Products, methods and uses

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008140200A1 (en) * 2007-05-10 2008-11-20 Seon-Il Kim External compositions for the skin
WO2011135059A1 (en) * 2010-04-29 2011-11-03 Leukolect As Human leukolectins and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TIAN WEIDONG ET AL: "How well is enzyme function conserved as a function of pairwise sequence identity?", 31 October 2003, JOURNAL OF MOLECULAR BIOLOGY, VOL. 333, NR. 4, PAGE(S) 863-882, ISSN: 0022-2836 *

Also Published As

Publication number Publication date
NO2358745T3 (ko) 2018-04-28
RU2528860C2 (ru) 2014-09-20
AU2009309477A1 (en) 2010-05-06
MX2011004483A (es) 2011-09-21
CL2011000947A1 (es) 2011-08-05
BRPI0920101A2 (pt) 2016-08-09
US10124034B2 (en) 2018-11-13
GB0819883D0 (en) 2008-12-03
US9260498B2 (en) 2016-02-16
JP5539372B2 (ja) 2014-07-02
CY1119930T1 (el) 2018-12-12
RU2011121616A (ru) 2012-12-10
WO2010049688A1 (en) 2010-05-06
BRPI0920101B1 (pt) 2021-11-23
CN102203127B (zh) 2019-05-28
KR20110095274A (ko) 2011-08-24
PT2358745T (pt) 2018-02-28
US20110280882A1 (en) 2011-11-17
AU2009309477B2 (en) 2014-12-18
CA2741823C (en) 2018-11-20
ES2658966T3 (es) 2018-03-13
JP2012506714A (ja) 2012-03-22
KR101448573B1 (ko) 2014-10-10
CN102203127A (zh) 2011-09-28
DK2358745T3 (en) 2018-03-05
NZ592911A (en) 2013-02-22
US20160151454A1 (en) 2016-06-02
CA2741823A1 (en) 2010-05-06
EP2358745A1 (en) 2011-08-24
ZA201103456B (en) 2012-08-29

Similar Documents

Publication Publication Date Title
US10124034B2 (en) Leukolectins and uses thereof
EP2563806B1 (en) Human leukolectins and uses thereof
US6613745B1 (en) Therapeutic molecules derived from snake venom
US20090143571A1 (en) Novel genes and their use in the modulation of obesity, diabetes and energy imbalance
WO1998053061A1 (en) Three novel genes encoding a zinc finger protein, a guanine, nucleotide exchange factor and a heat shock protein or heat shock binding protein
EP1402032A1 (en) Bcl-2-modifying factor (bmf) sequences and their use in modulating apoptosis
US6075129A (en) Protein molecules and uses therefor
EP1438427A1 (en) Nucleic acid markers for use in determining predisposition to neoplasm and/or adenoma
AU2002325088A1 (en) Nucleic acid markers for use in determining predisposition to neoplasm and/or adenoma
US6884617B1 (en) Isolated nucleic acid encoding murine musculin
AU774097B2 (en) A novel regulatory molecule and genetic sequences encoding same
US20060057665A1 (en) Galectin-14 therapeutic molecule and uses thereof
AU2002304971A1 (en) Bcl-2-modifying factor (Bmf) sequences and their use in modulating apoptosis

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110527

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL RS

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: LEUKOLECT AS

Owner name: WALTHER, BERNT TH

RAX Requested extension states of the european patent have changed

Extension state: RS

Payment date: 20110527

Extension state: AL

Payment date: 20110527

17Q First examination report despatched

Effective date: 20120411

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: LEUKOLECT AS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20170328

RIN1 Information on inventor provided before grant (corrected)

Inventor name: MIFTARI, MIRUSHE

Inventor name: WALTHER, BERNT, TH

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL RS

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: AT

Ref legal event code: REF

Ref document number: 950293

Country of ref document: AT

Kind code of ref document: T

Effective date: 20171215

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602009049623

Country of ref document: DE

REG Reference to a national code

Ref country code: NL

Ref legal event code: FP

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Ref document number: 2358745

Country of ref document: PT

Date of ref document: 20180228

Kind code of ref document: T

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 20180221

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

Effective date: 20180226

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2658966

Country of ref document: ES

Kind code of ref document: T3

Effective date: 20180313

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: NO

Ref legal event code: T2

Effective date: 20171129

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171129

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180228

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171129

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171129

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20180400518

Country of ref document: GR

Effective date: 20180627

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171129

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171129

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171129

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602009049623

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171129

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171129

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171129

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 10

26N No opposition filed

Effective date: 20180830

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171129

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20181029

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20171129

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20091029

Ref country code: MK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20171129

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180329

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20201022

Year of fee payment: 12

Ref country code: PT

Payment date: 20201019

Year of fee payment: 12

Ref country code: CY

Payment date: 20201020

Year of fee payment: 12

Ref country code: MC

Payment date: 20201023

Year of fee payment: 12

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211102

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220429

Ref country code: CY

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20211029

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20220506

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20231030

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20231030

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20231031

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20231101

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20231031

Year of fee payment: 15

Ref country code: NO

Payment date: 20231101

Year of fee payment: 15

Ref country code: IT

Payment date: 20231031

Year of fee payment: 15

Ref country code: IE

Payment date: 20231030

Year of fee payment: 15

Ref country code: FR

Payment date: 20231030

Year of fee payment: 15

Ref country code: FI

Payment date: 20231030

Year of fee payment: 15

Ref country code: DK

Payment date: 20231031

Year of fee payment: 15

Ref country code: DE

Payment date: 20231101

Year of fee payment: 15

Ref country code: CH

Payment date: 20231102

Year of fee payment: 15

Ref country code: AT

Payment date: 20231102

Year of fee payment: 15

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20231030

Year of fee payment: 15